LENSAR, Inc. Reports Q4 and Full Year 2025 Financial Results: Key Developments for Investors

Overview

LENSAR, Inc. (Nasdaq: LNSR), a global leader in advanced robotic laser solutions for cataract surgery, has released its financial and operational results for the fourth quarter and full year ended December 31, 2025. The company also provided crucial business updates that may have a significant impact on its share value and future outlook.

Key Financial Highlights

• ALLY System Adoption: 15 ALLY Robotic Cataract Laser Systems were placed in Q4 2025, bringing the total installed base to approximately 200 systems, a 48% year-over-year increase. There is a backlog of 13 ALLY systems pending installation as of year-end 2025.
• Installed Base Growth: The total combined installed base of LENSAR Laser Systems and ALLY Systems grew by 13% year-over-year to 495 systems.
• Recurring Revenue: Recurring revenue exceeded \$46.3 million for the full year 2025, marking a 15% increase over 2024. In Q4, recurring revenue grew by 17% year-over-year.
• Revenue Breakdown:
  • Total Q4 2025 revenue: \$16.0 million (down 4% compared to Q4 2024).
  • Full year 2025 revenue: \$58.4 million (up from \$53.5 million in 2024).
  • 79% of revenue in Q4 and full year 2025 came from recurring sources (up from 64% in Q4 2024 and 75% in FY 2024).
• Procedure Volume: Worldwide procedure volume for 2025 was 206,014, a 22% increase over 2024. Q4 2025 procedure volume grew 20% year-over-year.
• Cash Position: Cash, cash equivalents, and investments stood at \$18.0 million as of December 31, 2025, compared to \$22.5 million at the end of 2024. Despite the annual decrease, there was a \$1.1 million increase in Q4 2025.

Operational and Strategic Updates

• Alcon Transaction Termination: A major development was the mutual termination of the previously contemplated merger with Alcon Research, LLC. As part of the termination agreement, LENSAR will retain a \$10.0 million merger deposit, which will be recognized as other income in Q1 2026. The termination also led to a reduction of \$4.3 million in acquisition-related costs and a reclassification of \$5.0 million in accounts payable from current to long-term obligations.
• Acquisition-Related Costs: LENSAR incurred \$17.1 million in acquisition-related costs related to the Alcon merger, with \$13.8 million classified as accounts payable. These costs will be adjusted following the termination of the merger.
• EBITDA and Adjusted EBITDA:
  • Q4 2025 EBITDA: (\$0.4) million (significantly improved from Q4 2024 EBITDA of (\$17.7) million).
  • Q4 2025 Adjusted EBITDA: \$0.6 million (up from \$0.5 million in Q4 2024).
• Net Loss: Q4 2025 net loss was \$1.5 million (\$0.12 per share), a dramatic improvement from a net loss of \$18.7 million (\$1.61 per share) in Q4 2024. The improvement was mainly due to changes in the fair value of warrant liabilities.
• Operating Expenses: Q4 2025 operating expenses were \$11.9 million, up 41% year-over-year, primarily due to acquisition-related costs.

Management Commentary

President and CEO Nick Curtis emphasized the company’s resilience and strategic pivot following the unexpected Alcon transaction news, reaffirming the commitment to independent growth and expansion of the robotic laser cataract market. He highlighted strong ALLY adoption, robust procedure growth (22% worldwide for 2025), and the durability of the recurring revenue model (79% of total revenue).

The robust utilization of the ALLY system by surgeons globally underscores its compelling value proposition and provides a clear path for further revenue and business growth.

Risks and Forward-Looking Statements

• The termination of the Alcon merger may have implications for share value and could prompt legal proceedings.
• Ongoing risks include operating losses, regulatory hurdles, supply chain disruptions, competition, market acceptance, reimbursement challenges, and macroeconomic factors.
• Investors are advised to review risk factors in the company’s SEC filings for comprehensive disclosure.

Investor Call

LENSAR management will host a conference call and webcast to discuss these results and updates on March 31, 2026, at 8:30 a.m. ET. Details are available on the company’s Investor Relations website.

Summary of Shareholder-Relevant, Price-Sensitive Items

• Termination of Alcon Merger: Retention of \$10 million merger deposit as income, reduction and reclassification of acquisition-related costs, and resolution of merger-related liabilities.
• Significant improvement in net loss and positive adjusted EBITDA for Q4 2025, indicating potential turnaround in profitability metrics.
• Strong adoption and utilization metrics for ALLY, suggesting market acceptance and a pathway for recurring revenue growth.
• Increase in operating expenses due to acquisition-related costs—shareholders should monitor future expense normalization post-merger termination.
• Procedure volume growth and high recurring revenue percentage support the company’s business model durability.

Financial Tables (Selected Figures)

Conclusion

LENSAR, Inc.’s year-end 2025 results demonstrate strong growth in system adoption, procedure volume, and recurring revenue, offset by the impact of significant acquisition-related costs due to the terminated Alcon merger. The retention of the \$10 million merger deposit and improvements in adjusted EBITDA and net loss metrics are noteworthy for investors. The company’s ability to rapidly pivot post-transaction and maintain robust operational momentum could be a positive catalyst for future share performance, but risks remain, particularly related to the fallout from the terminated merger and ongoing operating losses.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties. Please refer to official filings for comprehensive risk disclosures.

View LENSAR, Inc. Historical chart here